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A B S T R A C T
Objectives: Pregabalin (PGB) is a newer antiepileptic drug (AED) licensed as add-on treatment for partial
epilepsy in adults. Efﬁcacy and safety have been proven in several controlled clinical studies. These trials,
however, only partially reﬂect clinical practice. Retention rate has been established as a marker for
efﬁcacy and safety of AEDs in long-term follow-up studies.
Methods: We evaluated the data of the ﬁrst 105 patients treated with PGB at Bethel Epilepsy Centre, a
tertiary referral centre for epilepsy. The patients were interviewed after 3, 6 and 12 months.
Results: 105 adult patients (aged 38  13 years) were treatedwith PGB, on average in combination with 2.1
AEDs (mean observation period 232 days). 76.2% had focal epilepsy, 19.0 multifocal epilepsy, and 3.8%
epilepsy with both focal and generalised seizures. 40% continued PGB with the following outcome: 5.7%
seizure-free for at least 1month (4.8% for at least 3months, 2.4% for at least 6months; one of the seizure-free
patients, however, had had epilepsy surgery during the observational period), 17.1% responders (50%
reduction of seizure frequency but not seizure-free), 13.3% with unchanged or increased seizure frequency.
Reasons for withdrawal were lack of efﬁcacy (47.6%) or side-effects (12.7%).
Conclusions: PGB is a new therapeutic option as add-on therapy for patients with highly refractory focal
epilepsies although the therapeutic success that can be expected in this group of patients is limited.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Pregabalin (PGB) is a newer antiepileptic drug (AED) licensed in
Germany and several other European countries as add-on
treatment for partial epilepsies as well as for generalised anxiety
disorder and neuropathic pain in adults. The putative mechanism
of action of PGB is to reduce the synaptic release of several
neurotransmitters by binding to the a2-d-protein.1 Efﬁcacy and
safety have been proven in several controlled studies.2–5 These
trials, however, only partially reﬂect clinical practice since they are
conducted in highly selected patient groups over only relatively
short treatment periods and have to obey ﬁxed treatment
schedules.6 Furthermore, adverse events that become overt only
after longer treatment periods or that occur only rarely may go* Corresponding author at: Bethel Epilepsy Centre, Dept. of General Epileptology,
Maraweg 21, D-33617 Bielefeld, Germany. Tel.: +49 521 772 78804;
fax: +49 521 772 78809.
E-mail address: christian.brandt@mara.de (C. Brandt).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.07.005undetected in short-term studies. One way of generating more
information is to assess the retention rate as a combined measure
of efﬁcacy and tolerability in long-term studies.7–9 This evaluation
was part of the quality-assurance process in our centre.
2. Methods
Bethel Epilepsy Centre is a tertiary referral centre for epilepsy.
All patients who had been started on PGB add-on therapy for
epilepsy between September 2004 and November 2005 have been
followed-up after 3, 6 and 12 months, mainly (80.9%) by
telephone-call. Treatment was started either on an in-patient or
an out-patient basis or while the patients were under the care of
the Berufsbildungswerk, a vocational training centre for young
adults with epilepsy. Data were collected prospectively as part of
clinical routine. As this was not a formal study, there were no
regulations concerning dose titration or target doses. Patientswere
also included for evaluation if they were treated with PGB beyond
the limits of licensing (‘‘off-label use’’). All patients were advised to
keep seizure diaries.vier Ltd. All rights reserved.
Table 1
Comedication on initiation of PGB (t0) and after 12 months (t12).
AED n (t0)
a Percenta,b n (t12) Percent
b
Lamotrigine (LTG) 47 (17) 44.76 (40.47) 17 40.48
Valproate (VPA) 40 (15) 38.10 (35.71) 11 26.19
Levetiracetam (LEV) 36 (16) 34.29 (38.10) 10 23.81
Carbamazepine (CBZ) 20 (9) 19.05 (19.15) 9 21.43
Oxcarbazepine (OXC) 18 (7) 17.14 (16.67) 9 21.43
Topiramate (TPM) 17 (7) 16.19 (16.67) 4 9.52
Phenytoin (PHT) 11 (2) 10.48 (4.76) 2 4.76
Phenobarbital (PB) 9 (6) 8.57 (14.29) 4 9.52
Benzodiazepines 9 (4) 8.57 (9.52) 1 2.38
Zonisamide (ZNS) 3 (0) 2.86 (0)
Bromide (BR) 2 (0) 1.90 (0)
Methsuximide (MSM) 2 (0) 1.90 (0)
Tiagabine (TGB) 2 (0) 1.90 (0)
Gabapentin (GBP) 1 (0) 0.95 (0)
Felbamate (FBM) 1 (0) 0.95 (0)
Primidone (PRM) 1 (0) 0.95 (0)
Total 219 (83) 67
Patients 105 (42) 42
a In brackets are ﬁgures for those patients who were still on PGB at t12.
b In relation to patients on initiation of PGB and after 12 months on PGB.
Fig. 1.Kaplan–Meier curve—retention rate of PGB after 12months. (n = 111 patients
who started with PBG, censored data (+) in 6 patients, see text).
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type and time-course, seizure frequency for each seizure type (for
the last week, last 4 weeks and last 3 months), occurrence of status
epilepticus (convulsive or non-convulsive), day of last seizure,
body-weight, dose titration and antiepileptic comedication.
Furthermore, patients were asked if they had had any adverse
events and—if PGB had been withdrawn—they were asked to state
the reasons for withdrawal. Special events (e.g. concomitant
illness) were documented. During follow-up, seizure frequency,
date of last seizure, body-weight and co-AEDswere documented in
the same form as in the initial documentation.
Statistical analysis was done with descriptive and explorative
methods. Response to PGB was evaluated by comparing seizure
frequency over all seizure types between a period of 4 weeks
before starting PGB and a period of 4 weeks before last follow-up.
In cases where only data about the last week were available (5 out
of 42 patients at t0 and 3 out of 42 at t12) the 4-week frequencywas
estimated from the available data (see Table 2).
Retention rate was the primary parameter, but efﬁcacy of PGB
was assessed additionally and classiﬁed as follows—seizure-free:
no seizures within the last 4 weeks (the exact periods of seizure-
freedom were documented); responder: seizure reduction 50% or
more compared to baseline but not seizure-free; non-responder:
change of seizure frequency less than 50%; worsening of seizure
frequency: increase of more than 50% compared to baseline.
A Kaplan–Meier curve was used to illustrate the time-course of
the retention rate.
Some patients could not be contacted exactly at the planned
time-points. If the last follow-up was done after 365 days, time of
evaluation was set back to 365 days.
Adverse events (AEs) were evaluated by open question. Besides
the spontaneous answers patients were explicitly asked for their
body weight.
3. Results
In total, 111 patients were started on PGB, but four patients
were lost to follow-up, and two died during the follow-up period
(censored data); 105 patients have been followed-up about 12
months or until PGB therapy was stopped (median follow-up
time = 221 days).
No post-mortem has been done in the two patients who died,
but therewas no apparent associationwith the PGB treatment. One
patient has been found dead in his apartment. This 32 years old
male patient had had episodes of status epilepticus before. Because
of this, it was assumed that he had died during status. The other, a
49-year-old male patient, had also a diagnosis of schizophrenia
and had refused sufﬁcient ﬂuid intake for several days during a
heat period and collapsed while being with a care-giver. It was
assumed that he had had a cardiac arrest.
Mean age of the 105 patients was 38.1  13.1 years (range 16.3–
80.9 years). The epilepsy syndromes were classiﬁed as focal in 80
patients (76.2%), multifocal in 20 (19.0%), as epilepsy with both focal
and generalised seizures in 4 (3.8%) and not classiﬁed in 1 (1%).
9 patients had a learning disability and 28 an intellectual
disability (13 mild, 11 moderate, 4 severe), and 40 patients had
another psychiatric diagnosis (23 personality disorder, 6 history of
or current psychosis, 7 anxiety disorder, 5 depression, 1
dysthymia; number exceeds 40 as some persons had more than
one diagnosis).
Sufﬁcient data about the drug history could be obtained in 87
patients. These patients had been treated with 8.2  2.6 AEDs as
mean in mono- or combination therapy before initiating PGB. For the
comedication on initiation of PGB see Table 1. Two patients were
started on PGB as second AED because of concomitant anxiety
disorder. 13 patients (12.4%) had already a vagus nerve stimulator.4. Titration of PGB
As this was not a formal study, no ﬁxed titration schemes were
set. Titration rates were adapted to the individual situation,
especially if AEs occurred. After 6 months, most patients were
treated with PGB doses within the recommended dose range
between 150 and 600 mg: 25.4%were on 300 mg/day and 28.8% on
600 mg/day (mean 430  210 mg/day, range 75–900 mg/day), and
after 12 months, 19.0% out of 42 patients were on 300 mg/day and
33.3% on 600 mg/day (523  185 mg/day, 200–900 mg/day).
5. Retention rate and response
42 (40%) out of 105 patients were still treated with PGB after 12
months. Reasons forwithdrawal in the 63 patients who terminated
PGB therapy were insufﬁcient efﬁcacy in 30 patients (47.6%),
adverse events in 8 (12.7%) and a combination of both in 21
(33.3%). See Fig. 1 for the retention rate.
After 12 months, 6 patients (5.7%) were seizure-free for at least
1 month (4.8% for at least 3 months, 2.4% for at least 6 months; see
Table 2 for seizure-frequencies at baseline). One of them, however,
had had surgical treatment for his epilepsy while being on PGB.
Table 2
Seizure frequencies at baseline and on follow-up in patients still on PGB.
Baseline seizure
frequency per last 4 weeks
all patients (n = 105)
n Baseline seizure
frequency per last
4 weeks (n = 42)
Follow-up (12 months)
seizure frequency per last
4 weeks (n = 42)
n pa
Median [25%, 75%] Median [25%, 75%] Median [25%, 75%]
All seizures types 18.5 [6.0, 30.8] 104b 14.0 [4.0, 28.0] 3.0 [1.8, 8.3] 38c <0.001
Simple partial 14.0 [4.0, 30.8] 36 6.5 [4.0, 34.0] 1.0 [0.0, 2.0] 12 0.077
Complex partial 12.0 [4.0, 28.0] 89 8.0 [2.0, 24.0] 3.0 [0.0, 8.5] 33 <0.001
Secondarily generalised tonic-clonic 3.0 [1.0, 5.0] 33 1.0 [0.3, 3.8] 0.0 [0.0, 1.8] 12 0.205
[25%, 75%] = 25% and 75% percentiles.
a Two-sided, exact Wilcoxon Test.
b Less than 105 because no sufﬁcient information was available in one patient.
c Less than 42 because no sufﬁcient information was available in four patients.
C. Brandt et al. / Seizure 18 (2009) 634–638636Information about the exact date of the last seizurewas available in
5 out of these 6 patients. Exact time of seizure freedomwas 43, 149,
156, 305 and 314 days.
Out of the responders (n = 18; 17.1%), a VNS had been implanted
in one, and one had had surgical treatment. None of the non-
responders had either brain operation or VNS implantation. 8
patients (7.6%) were non-responders, and another 6 (5.7%) had a
worsening of their seizure frequency of more than 50% compared
to baseline and in 63 patients (60.0%) PGB was withdrawn
(insufﬁcient information about four patients).
See Table 2 for changes of seizure frequencies from baseline to
12-month follow-up.
In the patient group still treated with PGB after 12 months
(n = 42), the number of concomitant drugs had been reduced from
2.0  0.75 to 1.6  0.63 (p < 0.01; two-sided, exact Wilcoxon-test).
All 42 patients were treated with concomitant AEDs. There were no
more patients with 5 AEDs (t0 3.8%, n = 4). See Table 1 for details.Table 3
Adverse events after 3, 6 and 12 months (t3, t6, t12).
Type of adverse event N (t3) Percent t3 (n = 105)
Weight gain 15 14.3
Tiredness 10 9.5
Cognitive disturbances 7 6.7
Gastrointestinal disturbances 5 4.8
Psychiatric disturbances 5 4.8
Ataxia 4 3.8
Increased appetite 4 3.8
Visual disturbances 4 3.8
Skin reactions 3 2.9
Edemas (hand/leg/foot) 3 2.9
Dizziness 3 2.9
Bladder incontinence 2 1.9
Loss of hair 2 1.9
Sedation 2 1.9
Disturbed sexual functions 2 1.9
Tremor 2 1.9
Fragile toe nails/ﬁnger nails 1 1.0
sGTCS after withdrawal (ﬁrst ever) 1 1.0
Hyperthyreosis 1 1.0
Headaches 1 1.0
Dry mouth 1 1.0
Myoclonias increased 1 1.0
Nervousness 1 1.0
Seizures more severe 1 1.0
Prolonged auras 1 1.0
Psychomotor slowing 1 1.0
Frequent falls during seizures 1 1.0
Seizure series
Increased urge to pass urine
Burning, red hands (dorsal side)
Decreased ability to fall asleep
Paresthesias
Nose bleed
a Number of patients exceeds 42 as patients were included who withdrew PGB betw6. Adverse events
See Table 3 for AEs. Most AEs were only transient, especially
during up-titration of PGB.
See Fig. 2 for changes of body weight under PGB.
7. Discussion
The efﬁcacy and safety of PGB as an AED have been proven in
several controlled studies.2–5 Recently, a Cochrane review
summarized that PGB when used as an add-on drug for
treatment-resistant partial epilepsy was signiﬁcantly more
effective than placebo at achieving a 50% or greater seizure
reduction.10 These studies, however, as premarketing studies in
general, provide only limited data about the usefulness of an
AED in clinical practice as they apply a rigid set of inclusion and
exclusion criteria, observe ﬁxed titration schemes and refer to aN (t6) Percent t6 (n = 65) N (t12) Percent t12 (n = 52)
a
11 16.9 8 15.4
5 7.7 2 3.8
6 9.2 1 1.9
4 6.2 3 5.8
5 7.7 3 5.8
2 3.1 2 3.8
1 1.5 4 7.7
1 1.5
4 6.2 3 5.8
2 3.1
3 4.7 1 1.9
1 1.9
1 1.5











een t6 and t12.
Fig. 2. Changes of body weight during treatment with PGB.
Number of patients after 12 months exceeds 42 as patients were included who
withdrew PGB between t6 and t12.
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placebo-controlled trials (RCTs) do provide information about
longer observation periods, represent, however, a selected
population insofar as they include only patients who completed
the preceding RCT.
Open studies like the one reported here offer information about
a broad population often not covered adequately by other types of
studies and give the opportunity to titrate the doses of the study-
drug and comedication individually. Patients included in our study
had highly refractory forms of epilepsy and also in many cases
learning or intellectual disability (37 patients) or psychiatric
comorbidity (40 patients). Obviously, the study has weaknesses: it
is more difﬁcult to get precise information about seizure
frequency, even more if the patient suffers from different seizure
types, and about side-effects by telephone interview. As there was
no ﬁxed protocol, not only the study-drug but also concomitant
drugs may have been changed or patients may have had epilepsy
surgery. The most robust parameter evaluated by our study is the
retention rate which is an accepted marker of combined efﬁcacy
and tolerability of AEDs.7–9
The retention rate of 40% for PGBafter 12months thatwe found
is slightly higher than that reported by Bauer who found 33 out of
103 patients still treated with PGB after 52 weeks11 and
comparable to the one reported by Huber in patients with
epilepsy and intellectual disability living in long-term residential
care (n = 33, retention rate after 12 months 40.6%).12 It is
considerably lower than the retention rate of 59.4% after 1-year
found by reviewing four long-term open-label studies.13 Prior to
participating in these studies, however, 968 out of 1.480 patients
had completed anRCT evaluating PGB so that these studies reﬂect,
as mentioned above, a selected population. The retention rate of
40% is also considerably lower than the rate of 60.4% found by
Carreno et al.14 It is, however, difﬁcult to compare that study due
to its retrospective character. It is possible that their patients had
less refractory epilepsies than ours as they had to have one to
three failed drugs before the introduction of PGB while ours had
8.2  2.6 failed AEDs before. The same applies for the audit study by
Valentin et al.15 who found a retention rate of 65% after 12months in
patients who had had a median number of 3 AEDs before
commencing PGB.15
Further data concerning efﬁcacy and tolerabilitywere collected.
After 12 months, 6 patients (5.7%) were seizure-free for at least 4
weeks before the last follow-up, 4.8% for at least 3months, 2.4% for
at least 6 months. As this was a purely observational study with no
restrictions according to comedication or other therapeutic
procedures, one of them had had surgical treatment for his
epilepsy, so the therapeutic success cannot simply be attributed to
the PGB treatment. The same limitation applies for those who
experienced an increase in seizure frequency, i.e. changes in co-
medication or other factors potentially inﬂuencing seizure-frequency may be (partially) responsible. This may, however, also
be true for other open-label studies. The seizure-free rate in our
study is smaller than that reported by Ryvlin (8.9% over the last 6
months and 5.8% over the last year of treatment) but the
limitations mentioned above do apply here again.13
It is surprising that 40% of the patients remained on PGB
therapy, but only 22.8% of patients experienced a clinically
relevant improvement of seizure frequency under PGB therapy
(sum of seizure-free patients and responders). Several hypoth-
eses have to be discussed: one is that they had an improvement
not of seizure frequency but of seizure severity which was not
assessed by the telephone interview. Another hypothesis is that
these patients experienced a positive psychotropic effect of PGB
which would be plausible as also anxiolytic properties have
been ascribed to the drug or that they had less side-effects than
under previous drugs. It may, however, be possible that doctors
tended to prescribe PGB further even in patients with no
detectable gain from the drug as these patients represent a
population with highly treatment-resistant epilepsies who had
no other therapeutic options or that doctors were reluctant to
change a therapeutic regimen initiated by a referral centre for
epilepsy.
PGB was generally well tolerated, weight gain being the most
frequently mentioned AE. As AEs were not assessed by systematic
questioning or examination but by spontaneous report to open
questioning, no further speciﬁcation of some AE categories is
possible, and the frequency of AEs may generally be under-
estimated.
8. Conclusions
Despite the above mentioned limitations it can be concluded
from our observational study in a naturalistic setting that PGB is
a new therapeutic option as add-on therapy for patients with
highly refractory focal epilepsies although the therapeutic
success that can be expected in this group of patients is generally
limited. Among the adverse events, weight gain seems to be the
most frequent, although not necessarily leading to withdrawal of
PGB.
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